Alnylam Pharma(DE:DUL)
€149.20+5.45 (+3.79%)
DE:DUL
Alnylam Pharma earnings date
€149.20
At close:+5.45 (+3.79%)
Alnylam Pharma (DUL) Q1 2026 Earnings Report
4 Followers
DE:DUL Q1 2026 EPS Results
- Actual EPS
- EUR 1.35
- Consensus EPS
- EUR 0.78
- Beat/Miss
- Beat by +EUR 0.57
- One Year Ago EPS
- -EUR 0.39
DE:DUL Q1 2026 Revenue Results
- Actual Revenue
- EUR 1.05B
- Expected Revenue
- EUR 998.77M
- Beat/Miss
- Beat by +EUR 46.26M
- YoY Revenue Growth
- +96.43%
Earnings Announcement Details
- Quarter
- Q1 2026
- Date
- 04/30/2026
- Time
- Before Open
- Conference Call
- Thursday, April 30, 2026
DE:DUL Upcoming Earnings
Alnylam Pharma's next earnings date is estimated for February 18, 2027, based on past reporting schedules.
Q1 2026 Earnings Call Audio
DE:DUL Q1 2026 Earnings Call
0:00 / 0:00
Q1 2026 Earnings Slide Deck
Q1 2026 Earnings Call Summary
No earnings call summary is available for this earnings event.
DE:DUL Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 18, 2027 | 2026 (Q4) | 1.54- | 0.73 | ― | ― |
| Oct 29, 2026 | 2026 (Q3) | 1.4914.07 | 1.65 | 754.35% (+12.43) | |
| Jul 30, 2026 | 2026 (Q2) | 1.461.08 | -0.46 | 337.25% (+1.54) | |
| Apr 30, 2026 | 2026 (Q1) | 0.781.35 | -0.39 | 443.18% (+1.75) | |
| Feb 12, 2026 | 2025 (Q4) | 1.030.73 | -0.58 | 226.15% (+1.32) | |
| Oct 30, 2025 | 2025 (Q3) | 0.501.65 | -0.78 | 311.49% (+2.43) | |
| Jul 31, 2025 | 2025 (Q2) | -0.49-0.46 | -0.12 | -292.31% (-0.34) | |
| May 01, 2025 | 2025 (Q1) | -0.80-0.39 | -0.47 | 15.38% (+0.07) | |
| Feb 13, 2025 | 2024 (Q4) | -0.53-0.58 | -0.98 | 40.91% (+0.40) | |
| Oct 31, 2024 | 2024 (Q3) | -0.82-0.78 | 1.03 | -175.65% (-1.81) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat Missed
